Disclosed herein are phenanthiroindolizidine derivatives of formula (I), wherein the substituents are as defined within the specification, processes for its preparation, compositions comprising said compounds and uses thereof. Said compounds are useful as Nuclear Factor-êB (NFêB) inhibitors and is therefore useful in the treatment of diseases associated with accelerated NFêB activity, such as cancer.